Strengthening local production of medicines and other health technologies to improve access
Member State requests for WHO’s support in strengthening local production have been increasing in recent years. The COVID-19 pandemic has only served to highlight even more the urgent need for enhancing quality manufacturing capacity in all regions of the world, including for innovative, highly effective health products such as mRNA technologies. Such capacity is necessary to address or even avert future public health emergencies and to improve access to health products in general through stronger health systems.
Sponsored by more than 100 countries, today’s resolution specifically calls for a more comprehensive, all-of-government approach, national strategies and action plans, an enabling business environment, human capital development, multi-stakeholder collaboration and engagement in regional and global networks.
WHO has already committed to holding the first ever World Local Production Forum in June this year, convening countries, partners and other stakeholders to discuss strategies to promote local production to improve access to health products during the current pandemic and beyond.
Global Action Plan for Healthy Lives and Wellbeing for All – SDG GAP
Delegates highlighted that the COVID-19 pandemic has reversed a decade of progress on SDG targets and underscored the need to redouble efforts by accelerating implementation of SDG3 GAP, WHO’s 13th general programme of work, and the Primary Health Care special programme.
There was wide support for the SDG3 GAP and WHO's convening role. Delegates noted the GAP’s key role in strengthening primary health care and advancing progress towards the targets set out in the Global Strategy on Women's, Children's and Adolescents' health. They also emphasized its focus on country-level impact and its critical role in supporting equitable and resilient recovery.
Extension of the Global Coordination Mechanism for Noncommunicable Diseases
The Global Coordination Mechanism (GCM) for Noncommunicable Diseases will be extended until 2030. The GCM was established in 2014.
A number of measures have been recommended to improve its effectiveness. These include development of a workplan for the delivery of the 5 functions for which the GCM has responsibility. The plan will include a clear vision, a robust results framework, performance and outcome indicators and clarity on how the mechanism will carry out its functions in a way that is integrated with WHO’s ongoing work on NCDs. The plan will be submitted to the World Health Assembly in 2022, after consideration by the Executive Board.
Practical tools for sharing knowledge and disseminating information about innovative activities from a variety of stakeholders working at country level will be developed. So will a global stock-take of action from various stakeholders at country level, together with guidance to Member States on engagement with non-State actors, including on the prevention and management of potential risks. Advice will be provided to civil society on how to develop national multi-stakeholder responses to NCDs and hold governments to account; and the capacity of people living with NCDs to participate in the co-creation of whole-of-society responses to NCDs will be strengthened.
- Final evaluation of the global coordination mechanism on the prevention and control of noncommunicable diseases. Executive summary – April 2021
- Options paper on the global coordination mechanism on the prevention and control of noncommunicable diseases
- Mid-point evaluation of the implementation of the WHO global action plan for the prevention and control of noncommunicable diseases 2013–2020
- Global Coordination Mechanism on the Prevention and Control of NCDs
- More on noncommunicable diseases